Dr. Stadler is a clinical trialist focused on developing novel therapies and biomarkers, especially for genitourinary cancer. In addition to an extensive history performing trials in kidney, bladder, and prostate cancer, he also has broad experience in leading efforts supporting clinical trial infrastructure and conduct. These include renal cancer cadre leader for the Cancer and Leukemia Group B (CALGB, now Alliance), PI for a DOD funded prostate cancer clinical trials consortium, co-PI for a Prostate Cancer SPORE, PI for the NCI funded N01 contract for early phase clinical trials, and a current role as Dean for Clinical Research